Nemaura Medical Completes 100 Patient Study For SugarBEAT 24-Hour Wear And Reports Interim Results
Portfolio Pulse from Benzinga Newsdesk
Nemaura Medical has completed a 100 patient study for its SugarBEAT 24-hour wear device, reporting interim results. The study was conducted on adults with Type 1 and Type 2 diabetes. The results indicate that a 24-hour sensor wear period using a single sensor is possible, which could allow users to monitor their glucose fluctuations overnight. The company is further evaluating the remaining cohorts and variables to establish the extent to which auto-calibration may be feasible.
September 11, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nemaura Medical's study results indicate that their SugarBEAT device could potentially be used for 24-hour glucose monitoring. This could enhance the product's appeal and usability, potentially leading to increased sales and revenue.
The news directly pertains to Nemaura Medical and its product, SugarBEAT. The positive study results could enhance the product's appeal to consumers, potentially leading to increased sales and revenue. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100